Close Menu
News JournosNews Journos
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
Editors Picks

Trump Administration Claims State Secrets Privilege in Kilmar Abrego Garcia Case

May 8, 2025

Fired FTC Commissioner Warns Trump Administration’s Actions Threaten Market Stability

March 19, 2025

Bukele Tweets Message to Trump After Meeting

April 15, 2025

Trump Tariffs Raise Investor Concerns Ahead of “Liberation Day”

April 2, 2025

Trump Considers Suspending Habeas Corpus for Migrants

May 9, 2025
Facebook X (Twitter) Instagram
Latest Headlines:
  • UK, Australia, and Canada Officially Recognize Palestinian State
  • Study Reveals iPhone Users More Susceptible to Online Scams Than Android Users
  • Cowboys’ George Pickens Reacts Emotionally on Bench During Game
  • Portugal Officially Recognizes Palestinian State, According to Foreign Minister
  • Trump Administration Expected to Associate Tylenol Use During Pregnancy with Autism Risk
  • Last-Minute Earthquake Tremors Felt Across Balıkesir, İzmir, and Istanbul
  • Memorial Service Celebrates Legacy of Conservative Activist Charlie Kirk
  • Uber to Launch Drone Food Delivery Pilot Program
  • Dwayne Johnson Takes on Dramatic Role in “The Smashing Machine”
  • Grocery Prices Rise: Three Key Factors Driving Costs Up
  • Germany’s Store Bans Jews in Protest of Israel’s Actions in Gaza
  • Sacramento TV Station Hit by Gunfire; Suspect in FBI Custody
  • Cyberattack Targets European Airports’ Systems
  • China Shifts Focus from Nvidia to Domestic Tech Initiatives
  • Walmart Marketplace Faces Surge in Counterfeits and Scams Amid Rapid Growth
  • Charlie Kirk’s Widow Takes Helm of Turning Point, Commits to Continuing His Mission
  • Frank Turek Delivers Heartfelt Tribute at Memorial for Charlie Kirk
  • AI Browsers More Vulnerable to Scams Than Humans, Study Finds
  • Cyberattack Disrupts Operations and Delays at Major European Airports
  • Memorial for Charlie Kirk Set for Sunday in Arizona, Featuring Erika Kirk as Speaker
Facebook X (Twitter) Instagram
News JournosNews Journos
Subscribe
Sunday, September 21
  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Turkey Reports
  • Money Watch
  • Health
News JournosNews Journos
You are here: News Journos » Business » Moderna’s Flu Vaccine Trials Show Promise for Combined Shot Development
Moderna's Flu Vaccine Trials Show Promise for Combined Shot Development

Moderna’s Flu Vaccine Trials Show Promise for Combined Shot Development

News EditorBy News EditorJune 30, 2025 Business 5 Mins Read

Moderna Inc. has announced promising results from its experimental mRNA-based flu vaccine, indicating a stronger immune response compared to existing vaccines in late-stage trials. This breakthrough positions the company favorably as it plans to resubmit its application for approval of both its standalone flu shot and a combination vaccine targeting influenza and COVID-19. The FDA’s recent review process reflects a complex regulatory landscape, yet Moderna is optimistic about its potential position as a leader in the market.

Article Subheadings
1) Overview of Moderna’s Latest Vaccine Development
2) Phase Three Trial Results and Efficacy
3) Regulatory Challenges and Company Response
4) Market Implications and Future Outlook
5) Summary of Health Impact and Community Response

Overview of Moderna’s Latest Vaccine Development

On March 26, 2024, Moderna Inc. announced that its experimental flu vaccine, based on mRNA technology, has outperformed existing flu shots during late-stage clinical trials. This marks a significant step for the company as it also aims to provide a combination vaccine that addresses both influenza and COVID-19. With the backdrop of a challenging flu season that resulted in heightened hospitalizations, this new development highlights the urgent need for more effective vaccines, especially among older populations. Moderna’s commitment to addressing this need underscores its potential to reshape the landscape of vaccine efficacy.

Phase Three Trial Results and Efficacy

The recently concluded phase three trial involved over 40,000 adults aged 50 and above. The participants were randomly assigned to receive a single dose of Moderna’s mRNA-1010 flu vaccine or a standard competitor vaccine. The findings revealed that Moderna’s vaccine exhibited an effectiveness rate that was 26.6% higher than the standard flu vaccine across the entire study population. Notably, the efficacy extended across major influenza strains, including A/H1N1, A/H3N2, and B/Victoria. Specifically, among adults aged 65 and older, the vaccine demonstrated a 27.4% higher effectiveness compared to the conventional vaccine.

Regulatory Challenges and Company Response

In May, Moderna proactively withdrew its application seeking approval for its combination vaccine, which targets both COVID-19 and influenza. The decision followed consultations with the Food and Drug Administration (FDA), particularly in light of recent changes to vaccine policies under the administration of Health and Human Services Secretary. These shifts influence regulatory scrutiny over vaccine efficacy and safety protocols. Moderna plans to resubmit its combination vaccine application, leveraging the recent trial data from its standalone flu vaccine. The company is currently in close discussions with the FDA to clarify regulatory requirements and expedite approval processes.

Market Implications and Future Outlook

Analysts suggest that if approved, Moderna’s flu vaccine could significantly impact the multi-billion-dollar vaccine market, which includes COVID-19, influenza, and respiratory syncytial virus (RSV). The market landscape is competitive, with Pfizer and Novavax also pursuing similar combination vaccines. Despite lacking specific revenue projections for these individual products, Moderna CEO Stephane Bancel expressed optimism, stating, “We’re clearly hoping our products will allow us to secure a fair share of these markets.” Furthermore, the anticipated approval could also lead to better logistical efficiencies within healthcare systems by simplifying vaccination protocols and improving patient compliance.

Summary of Health Impact and Community Response

The health implications of Moderna’s new vaccine are significant, particularly given recent data from the Centers for Disease Control and Prevention (CDC) that indicate a 15-year high in seasonal flu-related hospitalizations. Reports suggest that over 600,000 Americans required hospitalization due to flu-related conditions last year. In light of this, Stephen Hoge, head of research and development at Moderna, has emphasized the critical importance of introducing more effective vaccines to combat influenza. The consistent efficacy results of the mRNA-1010 vaccine across various demographics affirm its potential to diminish the burden of influenza, particularly among vulnerable populations.

No. Key Points
1 Moderna’s mRNA-based flu vaccine demonstrated a stronger immune response than current vaccines in trials.
2 A phase three trial showed the vaccine was 26.6% more effective than the standard flu vaccine.
3 Regulatory discussions with the FDA are ongoing to ensure compliance and expedite approval.
4 The vaccine could play a significant role in reducing healthcare costs and improving patient adherence to vaccination schedules.
5 Moderna aims to contribute significantly to the flu vaccine market, which is currently experiencing high demand.

Summary

Moderna’s advancements in mRNA-based vaccine technology highlight an important shift in the approach to influenza vaccination. The promising results from recent trials reinforce the urgent call for more effective flu vaccines, especially given the challenges posed by the recent flu season. As the company moves forward with regulatory applications, its commitment to improving public health through innovative solutions positions it as a potential leader in this critical healthcare segment.

Frequently Asked Questions

Question: What is the mRNA-1010 vaccine?

The mRNA-1010 vaccine is Moderna’s experimental influenza vaccine designed to provide a stronger immune response compared to existing flu shots, utilizing messenger RNA technology.

Question: Why did Moderna withdraw its application for the combination vaccine?

Moderna withdrew its application to ensure the submission included robust efficacy data from its phase three trial of its standalone flu vaccine, following consultations with the FDA.

Question: What potential benefits does the dual flu and COVID-19 vaccine offer?

The combination vaccine is expected to simplify vaccination processes, reduce healthcare workloads, lower costs, and improve patient uptake, thereby enhancing public health outcomes.

Business Ethics Business Growth Business News Business Technology combined Consumer Trends Corporate Finance Corporate Strategy Development Economic Outlook Entrepreneurship flu Global Business Innovation Investment Opportunities Leadership Management Market Trends Mergers & Acquisitions Modernas promise Retail Business shot Show Small Business Startups Supply Chain Trials Vaccine
Share. Facebook Twitter Pinterest LinkedIn Email Reddit WhatsApp Copy Link Bluesky
News Editor
  • Website

As the News Editor at News Journos, I am dedicated to curating and delivering the latest and most impactful stories across business, finance, politics, technology, and global affairs. With a commitment to journalistic integrity, we provide breaking news, in-depth analysis, and expert insights to keep our readers informed in an ever-changing world. News Journos is your go-to independent news source, ensuring fast, accurate, and reliable reporting on the topics that matter most.

Keep Reading

Business

Walmart Marketplace Faces Surge in Counterfeits and Scams Amid Rapid Growth

6 Mins Read
Business

Warehouse Clubs Expand Presence with New Stores and Membership Growth

7 Mins Read
Business

Trump Threatens Broadcast Station Licenses Amid Regulatory Debates

6 Mins Read
Business

FedEx Reports Q1 2026 Earnings Results

4 Mins Read
Business

Cracker Barrel Reports Q4 2025 Earnings Results

6 Mins Read
Business

NHL Commissioner Supports Olympic Participation for Players

6 Mins Read
Journalism Under Siege
Editors Picks

Republicans’ Favorability Toward Elon Musk Drops by 16 Points

June 11, 2025

Trump Directs Federal Authorities to Reopen Alcatraz for Violent Criminals

May 4, 2025

Trump Moves to Eliminate DEI Initiatives at Smithsonian Institutions

March 27, 2025

House GOP Embraces Trump Budget Plan Following Conservative Support

April 10, 2025

Trump Ally Named Interim U.S. Attorney for New Jersey Amid Ongoing Legal Challenges

March 24, 2025

Subscribe to News

Get the latest sports news from NewsSite about world, sports and politics.

Facebook X (Twitter) Pinterest Vimeo WhatsApp TikTok Instagram

News

  • World
  • U.S. News
  • Business
  • Politics
  • Europe News
  • Finance
  • Money Watch

Journos

  • Top Stories
  • Turkey Reports
  • Health
  • Tech
  • Sports
  • Entertainment

COMPANY

  • About Us
  • Get In Touch
  • Our Authors
  • Privacy Policy
  • Terms and Conditions
  • Accessibility

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

© 2025 The News Journos. Designed by The News Journos.

Type above and press Enter to search. Press Esc to cancel.

Ad Blocker Enabled!
Ad Blocker Enabled!
Our website is made possible by displaying online advertisements to our visitors. Please support us by disabling your Ad Blocker.
Go to mobile version